The mutational landscape of SARS-CoV-2 provides new insight into viral evolution and fitness.

Publication date: Jul 11, 2025

Although vaccines and treatments have strengthened our ability to combat the COVID-19 pandemic, new variants of SARS-CoV-2 continue to emerge in human populations. Because the evolution of SARS-CoV-2 is driven by mutation, a better understanding of its mutation rate and spectrum could improve our ability to forecast the trajectory of the pandemic. Here, we use circular RNA consensus sequencing (CirSeq) to determine the mutation rate of six SARS-CoV-2 variants and perform a short-term evolution experiment to determine the impact of these mutations on viral fitness. Our analyses indicate that the SARS-CoV-2 genome mutates at a rate of ∼1. 5 cD7 10/base per viral passage and that the spectrum is dominated by C → U transitions. Moreover, we find that the mutation rate is significantly reduced in regions that form base-pairing interactions and that mutations that affect these secondary structures are especially harmful to viral fitness. In this work, we show that the biased mutation spectrum of SARS-CoV-2 is likely a result of frequent cytidine deamination and that the secondary structure of the virus plays an important role in this process, providing new insight into the parameters that guide viral evolution and highlighting fundamental weaknesses of the virus that may be exploited for therapeutic purposes.

Open Access PDF

Concepts Keywords
Base COVID-19
Biased Cytidine
Covid Cytidine
Fitness Deamination
Vaccines Evolution, Molecular
Genetic Fitness
Genome, Viral
Humans
Mutation
Mutation Rate
RNA, Viral
RNA, Viral
SARS-CoV-2

Semantics

Type Source Name
disease MESH COVID-19 pandemic
drug DRUGBANK Tropicamide
disease MESH mutation rate
disease IDO role
disease IDO process
disease MESH Gout
drug DRUGBANK Cysteamine
disease MESH Lung Diseases
disease IDO host
disease MESH polio
disease MESH Dengue
disease IDO susceptibility
disease MESH infection
pathway KEGG Viral replication
pathway KEGG Virion
disease IDO cell
drug DRUGBANK Aspartame
drug DRUGBANK Coenzyme M
disease IDO virulence
drug DRUGBANK Isoxaflutole
drug DRUGBANK Cytidine
drug DRUGBANK Adenine
drug DRUGBANK Uracil
drug DRUGBANK Propylthiouracil
drug DRUGBANK Guanine
drug DRUGBANK Succimer

Original Article

(Visited 1 times, 1 visits today)